MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease
Jin Wang,Jinyun Chen,Ping Chang,Aimee Leblanc,Donghui Li,James L. Abbruzzesse,Marsha L. Frazier,Ann M. Killary,Subrata Sen +8 more
Reads0
Chats0
TLDR
Observations show the feasibility of developing plasma miRNA profiling as a sensitive and specific blood-based biomarker assay for pancreatic cancer that has the potential of translation to the clinic with additional improvements in the future.Abstract:
Development of minimally invasive biomarker assays for early detection and effective clinical management of pancreatic cancer is urgently needed to reduce high morbidity and mortality associated with this malignancy We hypothesized that if aberrantly expressing microRNAs (miRNA) in pancreatic adenocarcinoma tissues are detected in blood plasma, then plasma profiling of these miRNAs might serve as a minimally invasive early detection biomarker assay for this malignancy By using a modified protocol to isolate and quantify plasma miRNAs from heparin-treated blood, we show that miRNA profiling in plasma can differentiate pancreatic adenocarcinoma patients from healthy controls We have profiled four miRNAs, miR-21, miR-210, miR-155, and miR-196a, all implicated in the development of pancreatic cancer with either proven or predicted target genes involved in critical cancer-associated cellular pathways Of these, miR-155 has recently been identified as a candidate biomarker of early pancreatic neoplasia, whereas elevated expression of miR196a has been shown to parallel progression of disease The results revealed a sensitivity of 64% and a specificity of 89% with the analyses of plasma levels for this panel of four miRNAs The area under the receiver operating characteristic curve were estimated at 082 and 078 without and with leave-one-out cross-validation scheme, respectively These observations, although a "proof of principle" finding at this time, show the feasibility of developing plasma miRNA profiling as a sensitive and specific blood-based biomarker assay for pancreatic cancer that has the potential of translation to the clinic with additional improvements in the futureread more
Citations
More filters
Journal ArticleDOI
Identification of miR-16 as an endogenous reference gene for the normalization of urinary exosomal miRNA expression data from CKD patients.
Tim Lange,Sylvia Stracke,Rainer Rettig,Uwe Lendeckel,Jana Kuhn,Rabea Schlüter,Volkhard Rippe,Karlhans Endlich,Nicole Endlich +8 more
TL;DR: In this article, the miRNA expression levels were determined by RT-qPCR after the isolation of urinary exosomes from 33 chronic kidney disease (CKD) patients and from 5 healthy controls.
Journal ArticleDOI
Decreased serum miR-181a is a potential new tool for breast cancer screening.
Li-Juan Guo,Qing-Yun Zhang +1 more
TL;DR: Serum miR-181a may represent a novel biomarker for primary BC as well as for early stage BC diagnosis and in combination with other markers, serum miRNAs may improve the sensitivity of BC screening.
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions
TL;DR: Intra-tumoral miR-10b promotes PCC proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF–TGF-β cross-talk and enhances the expression of EMT-promoting genes, whereas decreasing theexpression of several metastasis-suppressing genes.
Journal ArticleDOI
Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy
TL;DR: A group of miRNA predictors in response to chemosensitivity for CRC patients are identified, which could lead to a significant improvement in chemotherapy regimen selection strategy and personalized CRC management.
Journal ArticleDOI
Pancreatic cancer stem cell markers and exosomes - the incentive push.
TL;DR: It is hypothesized that Pa-CSC markers play a decisive role in tumor progression and the possibility that CSC markers are the initial trigger for these processes and what is the special contribution of CSC-TEX.
References
More filters
Journal ArticleDOI
Analyzing real-time PCR data by the comparative C(T) method.
TL;DR: This protocol provides an overview of the comparative CT method for quantitative gene expression studies and various examples to present quantitative gene Expression data using this method.
Journal ArticleDOI
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
TL;DR: It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer.
Journal ArticleDOI
A microRNA expression signature of human solid tumors defines cancer gene targets
Stefano Volinia,George A. Calin,Chang Gong Liu,Stefan Ambs,Amelia Cimmino,Fabio Petrocca,Rosa Visone,Marilena V. Iorio,Claudia Roldo,Manuela Ferracin,Robyn L. Prueitt,Nozumu Yanaihara,Giovanni Lanza,Aldo Scarpa,Andrea Vecchione,Massimo Negrini,Curtis C. Harris,Carlo M. Croce +17 more
TL;DR: The results indicate that miRNAs are extensively involved in cancer pathogenesis of solid tumors and support their function as either dominant or recessive cancer genes.
Journal ArticleDOI
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
TL;DR: It is shown that the highly malignant human brain tumor, glioblastoma, strongly over-expresses a specific miRNA, miR-21, which may contribute to the malignant phenotype by blocking expression of critical apoptosis-related genes.
Related Papers (5)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases
Xi Chen,Yi Ba,Lijia Ma,Lijia Ma,Xing Cai,Yuan Yin,Kehui Wang,Jigang Guo,Yujing Zhang,Jiangning Chen,Xing Guo,Qibin Li,Qibin Li,Xiaoying Li,Wenjing Wang,Yan Zhang,Jin Wang,Xueyuan Jiang,Yang Xiang,Chen Xu,Pingping Zheng,Juanbin Zhang,Ruiqiang Li,Hongjie Zhang,Xiaobin Shang,Ting Gong,Guang Ning,Jun Wang,Jun Wang,Ke Zen,Junfeng Zhang,Chen-Yu Zhang +31 more
MicroRNA expression profiles classify human cancers
Jun Lu,Gad Getz,Eric A. Miska,Eric A. Miska,Ezequiel Alvarez-Saavedra,Justin Lamb,David Peck,Alejandro Sweet-Cordero,Alejandro Sweet-Cordero,Benjamin L. Ebert,Benjamin L. Ebert,Raymond H. Mak,Raymond H. Mak,Adolfo A. Ferrando,James R. Downing,Tyler Jacks,H. Robert Horvitz,H. Robert Horvitz,Todd R. Golub,Todd R. Golub,Todd R. Golub +20 more